Collaboration

#Artificial intelligence (AI) #Automation / robotics #Collaboration #Drug discovery #Pierre Fabre #XtalPi

Pierre Fabre and XtalPi team up on drug discovery

Pharmaceutical company Laboratoires Pierre Fabre and AI platform company XtalPi have announced a collaboration to discover novel drug candidates across oncology, rare diseases, and dermatology.  Under the agreement, XtalPi will use its integrated AI capabilities and robotics platform to de novo design and deliver novel small molecule… Read More

#Business & Investment #News

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Collaboration #ProBio #Therapeutic Antibodies

ProBio and AbTis partner on next-generation antibody-drug conjugate

CRDMO ProBio and South Korean biotechnology company AbTis have agreed an exclusive global licensing agreement for the development of antibody-drug conjugates (ADCs).  AbTis will receive exclusive global rights to develop and commercialise a discovery-stage therapeutic antibody asset generated through ProBio’s biologics discovery and development capabilities against an… Read More

#Business & Investment #News

Business deal agreement
#Antibody drug conjugate (ADC) #Boehringer Ingelheim #China #Collaboration #Oncology

Boehringer Ingelheim puts China strategy into action with SBP deal

Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.   Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s platforms and early-development capabilities… Read More

#Business & Investment #News

CRISPR gene editing
#Collaboration #CRISPR #CRISPR-Cas9 #RNA

CasZyme and Cirena to collaborate on developing longer guide RNAs

CasZyme and Cirena have signed an agreement to collaborate on optimising the editing efficiency of CasZyme’s Cas12l CRISPR nuclease in human-relevant applications using Cirena’s synthetic 150-170nt guide RNAs.  If successful, the work could improve editing efficiency of any resultant T-cell therapies (like CAR-T treatments), as well as… Read More

#Business & Investment #News

#ADME / Tox #Artificial intelligence (AI) #AstraZeneca #Collaboration #Drug safety #Tremont AI

Research collab will build AI solutions for accelerated safety screening

AstraZeneca and Tremont AI have announced a research collaboration to develop and evaluate AI solutions for accelerated safety screening in preclinical toxicologic pathology studies.  Assessing the safety of a new drug is one of the most demanding steps before it can reach patients.  Toxicologic pathologists… Read More

#News

Cancer tumour
#Collaboration #Georgiamune #Immunotherapy #Menarini #Solid tumours #Stemline Therapeutics

Menarini and Georgiamune sign deal for oral immunotherapy

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621.  GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours.   It is one… Read More

#Business & Investment #Cancer Research #News

#Artificial intelligence (AI) #AstraZeneca #Cardiometabolic diseases #Collaboration

AZ signs AI drug discovery deal with insitro

AstraZeneca and insitro have signed a worldwide exclusive research collaboration agreement to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.   Under the terms of the agreement, insitro will receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and… Read More

#Business & Investment #News

#Alentis Therapeutics #Collaboration #CSL #Phase II trial

CSL and Alentis announce global partnership

CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.  Under the terms of the agreement, Alentis will receive a… Read More

#Business & Investment #News #Trending News

Protein degrader
#Collaboration #Eli Lilly #Gate Bioscience #Protein degradation

Lilly and Gate agree $870m deal for molecular gate medicines

Eli Lilly and Gate Bioscience have expanded their collaboration to discover, develop, and commercialise molecular gate therapeutics.   The expanded collaboration adds one target, with the opportunity to add a second target, to the companies’ existing work.   The programmes leverage Gate’s Molecular Gate drug discovery engine… Read More

#Business & Investment #News

Cancer cells
#Cancer Research UK #Collaboration #Oncology #ORIC Pharmaceuticals

Cancer Research UK and ORIC partner on CIP2A-targeted therapy

Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.  Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More

#Cancer Research #News

Dollar sign on a tablet
#Collaboration #KRAS #MSD #Oncology #SciBrunch Therapeutics

MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion

SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.  Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide.   SciBrunch will receive… Read More

#Business & Investment #News

Red blood cells
#Collaboration #Defense Advanced Research Projects Agency (DARPA) #Metabolic diseases #Scarlet Therapeutics

Scarlet secures $14m DARPA deal for smart red blood cells

Scarlet Therapeutics has entered into an agreement with the Defense Advanced Research Projects Agency (DARPA) to advance the development of smart red blood cells (SRBCs).   Scarlet will lead a multidisciplinary consortium to develop SRBCs in a programme worth up to $14 million.  The agreement builds… Read More

#Business & Investment #News

#Collaboration #Drug delivery #Nanexa #Novo Nordisk #Peptides

Novo and Nanexa agree €1.165 billion drug delivery deal

A new agreement grants Novo a global exclusive license to Nanexa’s PharmaShell atomic layer deposition (ALD) drug delivery technology platform for certain therapeutic peptide drugs in indications including obesity, type 2 diabetes and other cardiometabolic diseases.  The collaboration includes development of long-acting injectable formulations with different administration-frequency… Read More

#Business & Investment #News

Novo Nordisk head office
#Anthropic #Artificial intelligence (AI) #Cardiometabolic diseases #Collaboration #Novo Nordisk

New deals boost Novo Nordisk’s AI drug discovery ambitions

Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases.   Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone… Read More

#Business & Investment #News

Bispecific antibodies
#Bispecific Antibodies #Collaboration #Dualitas Therapeutics #Roche

Roche and Dualitas Therapeutics agree $1b bispecific antibodies deal

Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases.  Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More

#Business & Investment #News

Radiopharmaceutical
#Collaboration #Radiopharmaceuticals #Ratio Therapeutics #RayzeBio

Ratio Therapeutics and RayzeBio advance novel radiopharmaceuticals

Ratio Therapeutics and RayzeBio have entered into a research collaboration and license agreement to advance a novel radiopharmaceutical programme focused on two undisclosed targets.  Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments,… Read More

#Business & Investment #News